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Abstract
Background: Cardiac resynchronization therapy (CRT) reduces morbidity and mortality in 
patients suffering from chronic heart failure (CHF). Optimal device programming is crucial 
for maximum patient benefit. The goal of the present study was to assess device settings from 
CHF patients undergoing CRT optimization in a “real world” setting, and to delineate para-
meters most frequently requiring adjustment.
Methods: All patients who underwent CRT device implantation in the Cardiology Clinic 
at the University Hospital Zurich between January 2011 and September 2012 and in whom 
follow-up was available were included in this analysis.
Results: A total of 170 CHF patients were included in this analysis. True biventricular pacing 
was present in 44% of all patients, while QRS fusion was detected in 49.9%. The majority 
of the patients presented with suboptimal atrioventricular (AV) delays requiring adjustment. 
AV delays were therefore shortened due to the presence of QRS fusion in 53.3% and 38.1% of 
patients (sAV and pAV, respectively) or prolonged because of truncation of the A wave in the 
left ventricular inflow pulse wave Doppler measurement (17.5% and 28.4% for sAV and pAV, 
respectively). In contrast, interventricular delay (VV delay) was rarely changed (11.9%).
Conclusions: In our “real world” cohort, a substantial proportion of patients presented to 
their first post-operative consultation with suboptimal device settings. Our data indicate that 
the opportunity to optimize device settings is frequently wasted in the “real world”, underlining 
the necessity for expert device follow-up to deliver optimal care to this challenging group of heart 
failure patients. (Cardiol J 2014; 21, 3: 316–324)
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Introduction
Cardiac resynchronization therapy (CRT) has 
become a cornerstone in the treatment of chronic 
heart failure (CHF) [1, 2]. Indeed, several clinical 
trials observed a reduction in morbidity and mor-
tality as compared to medical therapy alone in pa-
tients suffering from symptomatic left ventricular 
(LV) dysfunction (LV ejection fraction [LVEF] 
£ 35%) with a prolonged QRS duration (≥ 120 ms). 
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Nevertheless, almost 30% of patients do not exhibit 
an improvement in clinical symptoms or hemodyna-
mic parameters after CRT implantation (so-called 
“non-responders”) [3]. This lack of improvement 
may be due to pre-implantation characteristics such 
as large areas of scar tissue due to coronary artery 
disease or a lack of mechanical dyssynchrony [4]. 
Suboptimal LV lead position further represents 
a reason for a lack of benefit [4]. Additionally, 
however, some patients do not respond to CRT due 
to suboptimal CRT device settings, impairing LV 
filling (atrioventricular [AV] dyssynchrony) and/or 
persistent LV dyssynchrony [5].
At the University Hospital of Zurich, we imple-
mented a standard protocol by which every patient 
with a CRT device undergoes a complete device op-
timization 3–6 months after implantation and again 
on a yearly basis or if clinically deemed necessary. 
The goal of the present study was to summarize 
clinical presentation, echocardiographic findings, 
and device settings from CHF patients undergo-
ing CRT optimization in this “real world” setting, 
unraveling the amount of patients presenting with 
suboptimal settings, as well as the parameters 
most frequently requiring adjustment. We pro-
vide a rationale for the necessity of implementing 
a routine protocol for the integrated management 
of these complex CHF patients, including expert 
device management.
Methods
Study population and CRT implantation
All patients with a CRT device receiving 
their first device follow-up in our specialized de-
vice clinic from January 1st 2011 until September 
2012 were prospectively included. The study was 
approved by the cantonal ethics committee Zurich. 
Mean time from implantation to optimization was 
2.9 months (Table 1). Indications for CRT implan-
tation were based on current guidelines [1]. CRT 
devices were implanted by a standard procedure 
under local anesthesia. Devices and leads from 
Biotronik, Boston Scientific/Guidant, Medtronic 
and St. Jude Medical were used. For implantation of 
the LV lead, percutaneous placement into a lateral 
or postero-lateral vein was attempted whenever 
possible. If no suitable vein branch was available, 
epicardial lead implantation was performed.
Follow-up protocol
We implemented a standard protocol by 
which every patient with a CRT device underwent 
a comprehensive and standardized device follow-up 
and optimization procedure (Fig. 1). After a comple-
te clinical assessment by a heart failure specialist, 
a comprehensive device follow-up was performed 
Table 1. Demographics at implantation.
Men [years] 130/170 (76.5%)
New implantation 129/170 (75.9%)
CRT upgrade 41/170 (24.1%)
Time implantation  
— optimization [months]
2.9 ± 5
Age at implantation [years] 62.8 ± 12.5
Ischemic cardiomyopathy 75/169 (44.4%)
CRT-D 156/170 (91.8%)
Sinus rhythm at implantation 107/167 (64.1%)
CRT — cardiac resynchronization therapy
Figure 1. Cardiac resynchronization therapy patient 
follow-up algorithm as implemented at the University 
of Zurich. See text for details, AVD — atrioventricular 
delay; VVD — interventricular delay.
Reassess AVD 
for ECG 
fusion if VVD 
has been 
adjusted
12-lead ECG, including:
— Intrinsic rhythm
— Right ventricular pacing
— Left ventricular pacing
Wrap up
— Print 12-lead ECG with current setting
— Print current device settings
— Comprehensive report, including
 rationale for setting changes
— Review with heart failure specialists 
 and discuss pertinent findings
Echocardiography
— Standard examination 
 (if required)
— AVD optimization
— Assessment of VV 
 dyssynchrony (TDI)
— VVD optimization, if required
AVD optimization (12 lead ECG)
— Assess “True biventricular“ 
 paced rhythm
— Start at lowest possible AVD
— Incremental increase of AVD 
 until signs of fusion on ECG
— Repeat for sensed and paced AVD
Complete device check
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by implantable electronic cardiac device specia-
lists (JS/DH), including complete check of the 
system with 12-lead electrocardiogram (ECG), 
and review of all brady- and tachycardia parame-
ters. Subsequently, a complete echocardiographic 
exam was performed (Vivid E9, GE), followed by 
optimization of the AV- and interventricular (VV) 
delay if necessary. AV delay optimization was 
performed starting at a long AV-delay without 
intrinsic conduction. The AV-delay was then 
progressively shortened in steps of 20 ms until 
truncation of the A-wave was observed. Then, the 
AV-delay was prolonged in 10 ms steps until the 
optimal separation of E/A wave without truncation 
of the A-wave was reached, which was considered 
the optimal AV-delay.
Results
Study population
A total of 170 CHF patients were included in 
this prospective analysis. Baseline demographic 
data at implantation, as well as clinical characteri-
stics at time of follow-up are summarized in Table 1. 
The majority of patients were men (76.5%), and 
had a cardiovascular risk profile typical of a real-
-world CHF cohort as previously shown [6]. All 
patients were on optimal medical therapy inclu-
ding angiotensin converting enzyme-inhibitors 
or angiotensin-II-blockers (95.2%), beta-blockers 
(93.5%) and diuretics (86.3%) prior to implantation. 
Furthermore, more than 50% of patients were 
treated with an aldosterone antagonist (55.4%) in 
addition to standard diuretic therapy, and received 
anti-arrhythmic treatment with either digitalis 
(13.1%) or amiodarone (17.9%) (Table 2).
Echocardiographic and electrocardiographic 
parameters at follow-up
Most patients demonstrated a reduced LVEF 
(mean 37.3 ± 11.1%) and a dilated LV (end-diastolic 
volume index 88.4 ± 41.6 mL/m2; Table 3). Of 
note, parameters of dyssynchrony at this time 
mainly demonstrated values within our lab’s pre-
defined normal values (interventricular mechanical 
delay — IVMD < 40 ms, tissue Doppler ima-
ging — TDIseptal-lateral < 60 ms, TDIanteroseptal-posterolateral 
< 60 ms), with an IVMD of 17.5 ± 27.7, as well as 
32.7 ± 46.8 ms and 33.5 ± 46.3 ms for septal-lateral 
and anteroseptal-posterolateral delay assessed by 
TDI, respectively. The mean intrinsic QRS dura-
tion was 150 ± 26.6 ms with an ECG pattern of 
left bundle branch block in the majority of cases 
(59.5%), and an average PQ interval of 184.7 ± 
± 27.6 ms (Table 4). At the time of implantation and 
at the first follow-up, most patients were in sinus 
rhythm (65.9%). While 65.3% of the patients had 
the same rhythm at our follow-up visit, a minority 
of patients switched from atrial fibrillation to sinus 
rhythm (2.4%) and vice versa (4.8%).
Device settings and intervals  
at the time of optimization
True biventricular pacing was present in ne-
arly half of the patients at the time of optimization 
(44.7%), while QRS fusion could be detected in 
39.4% of cases (Table 5, Fig. 2). At the time of 
optimization, average sensed AV (sAV) delay was 
110.5 ± 19 ms and paced AV (pAV) 136.5 ± 23.4 ms. 
QRS fusion, as diagnosed by 12-lead surface ECG, 
began to appear at an average sAV of 103.9 ± 
± 37.1 ms and an average pAV of 136.5 ± 23.4 ms, 
respectively.
A biventricular pacing rate of more than 95% 
was present in 85.8% of patients from the studied 
cohort. The main reason for a low biventricular 
pacing percentage was either atrial fibrillation or 
Table 2. Clinical parameters at time of optimization.
Clinical parameters
Height [m] 1.7 ± 0.1
Weight [kg] 82 ± 18.5
Body mass index [kg/m2] 28.4 ± 5.9
Systolic BP [mm Hg] 116.1 ± 17.3
Diastolic BP [mm Hg] 73 ± 11.7
NYHA class:
NYHA I 24/134 (17.9%)
NYHA II 54/134 (40.3%)
NYHA III 20/134 (14.9%)
NYHA IV 1/134 (0.7%)
Medication
Beta-blocker 157/168 (93.5%)
ACE-I/ARB 160/168 (95.2%)
Aldosterone antagonist 93/168 (55.4%)
Other diuretics 145/168 (86.3%)
Digitalis 22/168 (13.1%)
Amiodarone 30/168 (17.9%)
CCB 11/168 (6.5%)
Nitrates 11/168 (6.5%)
Lipid lowering treatment 103/168 (61.3%)
Aspirin 84/168 (50%)
Clopidogrel 12/168 (7.1%)
Oral anticoagulation 84/168 (50%)
ACE-I/ARB — angiotensin-converting-enzyme inhibitors/angiotensin 
II receptor blockers; BP — blood pressure; CCB — calcium channel 
blocker; NYHA — New York Heart Association classification
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frequent ventricular extrasystoles. At the time 
of follow-up, mean programmed VV delay was 
8.5 ± 14.4 ms (LV first).
Left ventricular lead settings
In a third of all cases, lead pacing configuration 
was “true” bipolar from the LV lead tip (LvTip) to 
the LV ring (LvRing; 34.1%) or between LvTip to 
the right ventricular lead ring (RvRing; 28.2%, 
Table 6). In every fifth patient, the pacing vector 
was between the LvTip and the coil of the right 
ventricular lead (RvCoil; 23.5%). With these config-
urations, only a minority of patients (n = 7, 4.2%) 
were suffering from diaphragmatic capture (4.2%), 
which was solved in all cases by reprogramming.
Table 3. Echocardiography at optimization.
LVEF [%] 37.3 ± 11.1
LVEDD [mm] 6.2 ± 1.1
LVESD [mm] 4.9 ± 1.3
EDV [mL] 169.5 ± 79.2
EDV index [mL/m2] 88.4 ± 41.6
ESV [mL] 110.8 ± 71.5
ESV index [mL/m2] 58.8 ± 38.3
Diastolic dysfunction:
No diastolic dysfunction 92/168 (54.8%)
Grade I 7/168 (4.2%)
Grade II 1/168 (0.6%)
Grade III 0/168 (0%)
Mitral regurgitation:
Minimal 88/167 (52.7%)
Mild 59/167 (35.3%)
Moderate 13/167 (7.8%)
Severe 4/167 (2.4%)
LAESD [mm] 4.7 ± 0.9
RV: Area D [cm2] 16.2 ± 5.1
Fractional shortening RV [%] 39.7 ± 12.1
TAM [mm] 18.3 ± 4.9
RV/RA-pressure gradient [mm Hg] 27.9 ± 11.6
RA size 5 ± 0.9
Dyssynchrony assessment:
RV-PEP [ms] 118.1 ± 31.3
LV-PEP [ms] 135.5 ± 31.5
IVMD 17.5 ± 27.7
TDI SL 32.7 ± 46.8
TDI AS-IL 33.5 ± 46.3
Diastolic filling time/RR-interval 49.5 ± 32.1
AS-AL — anteroseptal-posterolateral; EDV — end-diastolic volume; 
ESV — end-systolic volume; IVMD — interventricular mechanical 
delay; LAESD — left atrium end-diastolic diameter; LV — left ven-
tricle; LVEF — left ventricular ejection fraction; LVEDD — left ventri-
cular end-diastolic diameter; LVESD — left ventricular end-diastolic 
diameter; PEP — preejection period; RV — right ventricle; RA —  
right atrium; SL — septal lateral; TDI — tissue Doppler imaging; 
TAM — tricuspid annular movement
Table 4. Electrocardiogram parameters.
Rhythm at optimization
SR 112/170 (65.9%)
SR, AVB III°, without  
ventricular escape
15/170 (8.8%)
SR, AVB III°, with  
ventricular escape
6/170 (3.5%)
AF with AV conduction 20/170 (11.8%)
AF, AVB III° 7/170 (4.1%)
AF post AV node ablation 6/170 (3.5%)
PQ intrinsic 184.7 ± 27.6
QRS intrinsic 150 ± 26.6
Bundle branch block:
No block 14/163 (8.6%)
LBBB 97/163 (59.5%)
RBBB 13/163 (8%)
AVB III° 36/163 (22.1%)
Development of rhythm
Unchanged 109 (65.3%)
AF Æ SR 4 (2.4%)
AF Æ PM 2 (1.2%)
SR Æ AF 8 (4.8%)
SR Æ PM 4 (2.4%)
PM upgrade 41 (24%)
AF — atrial fibrillation; AV — atrioventricular; AVB — atrioventricu-
lar block; LBBB — left bundle branch block; RBBB — right bundle 
branch block; PM — pacemaker; SR — sinus rhythm
Optimization of CRT settings  
after implantation
In the majority of all patients who underwent 
CRT device implantation, the programmed AV in-
tervals were deemed suboptimal during follow-up 
and were subsequently reprogrammed (Table 7). 
AV delays were shortened (sAV delay in 53.3%, 
pAV delay in 38.1% of the patients) mainly due to 
the presence of QRS fusion on the 12-lead ECG. In 
contrast, the AV delay was prolonged in only 17.5% 
and 28.4% (sAV and pAV, respectively), mostly due 
to truncation of the A wave in the LV inflow pulse 
wave Doppler measurement. In 77 patients (45% 
of the entire cohort), some degree of QRS fusion 
was accepted in order to allow for better LV filling.
In contrast to the adjustments of the AV inter-
val, the VV delay was left unchanged in the majority 
of patients (88.1%). The main reason for a change 
in VV delay was intraventricular dyssynchrony 
observed on TDI (82.4%).
Thirty three (19.4%) patients in our cohort 
suffered from atrial fibrillation. By virtue of this, AV 
optimization was impossible in these patients and 
VV optimization greatly impaired. Of our patients 
with atrial fibrillation, 20 (61%) had intrinsic con-
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duction, whereas 7 (21.2%) and 6 (18.2%) patients 
had no intrinsic AV conduction or had undergone 
AV node ablation, respectively (Table 4).
Discussion
The aim of the present study was to give an 
overview on CRT settings at the time of device 
implantation and to demonstrate the potential for 
optimization by comprehensive assessment during 
Table 5. AV/VV settings at optimization.
Pacing at optimization:
True biventricular stimulation 76/170 (44.7%)
Fusion 67/170 (39.4%)
Pseudofusion 3/170 (1.8%)
Atrial fibrillation 23/170 (13.5%)
AV delays:
sAV (at interrogation) 110.5 ± 19
pAV (at interrogation) 136.5 ± 23.4
Begin QRS fusion (sAV) 103.9 ± 37.1
Begin QRS fusion (pAV) 174.3 ± 42.7
Intraatrial delay (pAV-sAV) 71.9 ± 28.2
No fusion (AV block) 33 (19.4%)
Dynamic AV delay on 78/164 (47.6%)
Situation at sensed AV delay 120 ms:
Pure biventricular stimulation 58/140 (41.4%)
Fusion 72/140 (51.4%)
Intrinsic rhythm/Pseudofusion 8/140 (5.7%)
Status before optimization:
A-wave truncation 38/147 (25.9%)
QRS fusion 39/147 (26.5%)
Both A-wave truncation  
and QRS fusion
31/147 (21.1%)
VV (at interrogation) [ms] 8.5 ± 14.4
Biventricular pacing (average) [%]: 94.3 ± 13.3
≥ 97% 112 (67.9%)
< 97% 53 (32.1%)
< 95% 40 (24.2%)
< 90% 23 (13.9%)
£ 85% 16 (9.7%)
Reason for low biventricular pacing (< 95%):
Atrial fibrillation 18/39 (46.2%)
VES 13/39 (33.3%)
Intrinsic conduction 3/39 (7.7%)
Other 4/39 (10.3%)
Device manufacturer:
Medtronic 31/170 (18.2%)
St. Jude Medical 49/170 (28.8%)
Biotronik 79/170 (46.5%)
Boston Scientific 10/170 (5.9%)
AV — atrioventricular; sAV — sensed AV; pAV — paced AV; VV — 
interventricular; VES — ventricular extrasystoles
Figure 2. Twelve-lead electrocardiograms (ECGs) of 
a patient presenting for cardiac resynchronization 
therapy optimization. “True” biventricular pacing (VVI 
90 bpm, left panel), intrinsic rhythm (right panel) and 
rhythm at follow-up (middle panel) are shown. Note 
the significant degree of QRS fusion as demonstrated 
by 12-lead ECG with the current device settings. QRS 
fusion is best appreciated in I, aVL and V3, indicating 
the necessity for comprehensive 12-lead ECG analysis 
in the follow-up of these patients.
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follow-up in an integrative device clinic. In view of 
the substantial discrepancy between programmed 
parameters and optimal values, our data indicate 
that this opportunity is frequently missed in the 
“real world”, providing a rationale for the necessity 
of protocol-oriented expert follow-up and optimiza-
tion procedures for these patients.
AV delay optimization and QRS fusion
Whether and how AV intervals should regular-
ly be evaluated and adjusted remains a matter of 
debate [7–9]. In various preliminary studies, opti-
mization of the AV delay has been demonstrated to 
significantly increase hemodynamic response, New 
York Heart Association (NYHA) class, LVEF and 
B-type natriuretic peptide level in the short-time 
follow-up [10–14]. In contrast, the recently pub-
lished SmartDelay determined AV Optimization: 
A comparison to Other AV Delay Methods Used in 
Cardiac Resynchronization Therapy (SMART-AV) 
trial implied otherwise. In this study, CRT device 
recipients were randomized to a fixed empirical 
AV delay of 120 ms, an echocardiographically 
optimized AV delay or a device-based AV optimi-
zation algorithm (SmartDelay) [15]. The primary 
endpoint, LV end-systolic volume at 6 months after 
implantation did not differ between the 3 groups. 
As discussed by the authors, it may be possible that 
the observed acute beneficial hemodynamic effects 
after CRT implantation are not sufficient enough to 
result in an improvement of hard clinical endpoints. 
On the other hand, the follow-up period of only 
6 months may have been too short to evaluate 
such endpoints.
Furthermore, it has to be kept in mind that 
the optimal AV delay may have a high variability 
among CRT patients [5, 16]. As such, data from 
SMART-AV do not imply that individual patients 
with suboptimal AV delay may not profit from an 
optimization procedure. Indeed, this has been 
substantiated most recently in a subanalysis from 
MADIT-CRT, in which patients with short AV-de-
lays (notably < 120 ms) had a superior outcome 
compared to those with longer AV delays [17]. Our 
data demonstrate that programming an empirical 
setting of 120 ms for the sensed AV delay was 
suboptimal in terms of true biventricular stimula-
tion in the vast majority of patients (57.1%), and 
8 (5.7%) patients even demonstrated entirely 
intrinsic conduction or pseudofusion (and hence 
loss of biventricular pacing) at this setting. Fur-
thermore, a subanalysis of the Clinical Evaluation on 
Advanced Resynchronization (CLEAR) pilot study 
revealed that systematic CRT optimization was 
Table 6. Left ventricular lead parameters.
Left ventricular pacing configuration:
LvTip-LvRing 58/170 (34.1%)
LvRing-LvTip (inverse bipolar) 5/170 (2.9%)
LvTip-RvRing 48/170 (28.2%)
LvRing-RvRing 9/170 (5.3%)
LvTip-RvCoil 40/170 (23.5%)
LvRing-RvCoil 7/170 (4.1%)
Unipolar 1/170 (0.6%)
Diaphragmatic capture:
No diaphragmatic capture 161/168 (95.8%)
Diaphragmatic capture,  
resolved with reprogramming
7/168 (4.2%)
Diaphragmatic capture, not ame-
nable to programming changes
0/168 (0%)
Threshold left ventricle [V] 1.3 ± 0.8
Threshold left ventricle [ms] 0.5 ± 0.2
Left ventricular sensing [mV] 12.6 ± 8.6
Left ventricular impedance [Ohm] 644.4 ± 228.3
Lv — left ventricle Rv — right ventricle
Table 7. Changes during optimization.
Change in sensed AV delay
Unchanged 39/137 (28.5%)
Shortened 73/137 (53.3%)
Lengthened 24/137 (17.5%)
Changes in paced AV delay
Unchanged 45/134 (33.6%)
Shortened 51/134 (38.1%)
Lengthened 38/134 (28.4%)
Reason for AV delay change
ECG fusion 56/97 (57.7%)
LV inflow truncation 23/97 (23.7%)
LV inflow fusion 14/97 (14.4%)
Visual LV filling 3/97 (3.1%)
Other 1/97 (1%)
Status after optimization
A-wave truncation 22/147 (15%)
QRS fusion 47/147 (32%)
Both A-wave truncation 
and QRS fusion
34/147 (23.1%)
Change in VV delay
Unchanged 118/168 (70.2%)
LV earlier 13/168 (7.7%)
RV earlier 5/168 (3%)
Dyssynchronous,  
not improvable
30/168 (17.9%)
Reason for VV delay changes
Visual 3/17 (17.6%)
Tissue Doppler imaging 14/17 (82.4%)
AV — atrioventricular; ECG — electrocardiogram; LV — left ventric-
le; RV — right ventricle; VV — interventricular
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associated with a higher percentage of improved 
patients based on the composite endpoint (all-cause 
mortality, heart failure-related hospitalization, 
NYHA functional class, and quality of life score), 
fewer deaths and fewer hospitalizations [18]. These 
data clearly indicate a role for CRT optimization 
over standard programming in all patients.
Moreover, the mean interatrial delay was 
markedly longer (71.9 ± 28.2 ms; Table 5) than the 
standard programmed difference between sensed 
and paced AV delay (usually 30–40 ms) found in the 
default settings, further supporting an individuali-
zed approach to AV delay programming.
The majority of our patients (> 70%) unde-
rwent reprogramming of the AV delay. One of the 
most important parameters to guide AV delay op-
timization is the level of true biventricular pacing 
or, vice versa, the degree of QRS fusion as a result 
of intrinsically conducted ventricular excitation 
[19–21]. In our cohort, 45.3% of patients presented 
with an AV delay too long to avoid any QRS fusion. 
However, whether some degree of ventricular fu-
sion may be clinically beneficial remains a matter of 
debate, as a certain amount of QRS fusion has been 
shown to improve hemodynamics [22–24]. Fusion 
allows for intrinsic excitation of the right ventricle 
via the normal-conducting right bundle branch 
which may result in improved right ventricle con-
traction [25]. A recent study further demonstrated 
that the maximal rate of LV pressure increase 
(dP/dt) was higher in LV pacing combined with 
intrinsic conduction as compared to biventricular 
pacing [22]. Based on these data, we accepted some 
degree of QRS fusion in order to allow for optimal 
LV filling in those cases where it was impossible 
to shorten the AV delay to the point of complete 
loss of QRS fusion (Fig. 2). Importantly, intrinsic 
conduction and pseudofusion could entirely and 
sustainably be avoided in all patients presenting 
with these findings.
VV delay optimization
For various reasons, VV delay optimization 
appears to be less important as compared to AV 
delay optimization. Even though an improvement 
in hemodynamic conditions has been observed 
after optimization of VV intervals [26–28], other 
randomized trials failed to find a beneficial effect 
[29, 30]. The latter may, at least in part, be due to 
the fact that VV delay optimization was performed 
in the majority of patients on top of AV delay opti-
mization. In a small study investigating the effect 
of simultaneous AV and VV time optimization, an 
additional but smaller beneficial effect of VV delay 
optimization was found [31]. In our cohort, only a mi-
nority of patients underwent VV optimization, mai-
nly due to the fact that it was not deemed necessary 
due to satisfying echocardiographic dyssynchrony 
parameters and, coherently, visual impression of 
synchronous LV contraction. In patients who were 
optimized, the indication was mainly driven by TDI 
values during echocardiographic evaluation. Con-
versely, 30 (17.9%) patients were dyssynchronous 
either visually or by TDI measurements, but could 
not be corrected by advancing left or right ventricle 
activation. As a result, and due to the lack of clear 
evidence for a benefit, VV optimization is only per-
formed in special cases in our institution.
CRT in patients with atrial fibrillation
19.4% of patients in our cohort suffered from 
atrial fibrillation. These patients pose a challenge in 
CRT as the uncoordinated and often rapid intrinsic 
conduction often results in a substantially impaired 
rate of biventricular pacing (< 95%). Indeed, atrial 
fibrillation was the main reason for a low percen-
tage of biventricular pacing in our cohort. Phar-
macologically, amiodarone has been shown to be 
most effective and safe for rhythm control in atrial 
fibrillation patients with heart failure [32], and, 
as a consequence, is frequently used to increase 
the percentage of biventricular stimulation. If the 
medical therapy is insufficient, AV nodal ablation is 
recommended as the next step [33]. In our cohort, 
39.4% of patients with atrial fibrillation ultimately 
had no intrinsic AV conduction and, consequently, 
had a high degree of biventricular pacing.
Limitations of the study
Our study has some inherent limitations. Data 
are only collected from a single tertiary care center, 
and may hence not be generalizable to other health-
care settings. We do, however, believe that most 
interpretations and statements characteristically 
reflect the situation of “real world” CRT patients, 
and are therefore important for therapy optimiza-
tion of these individuals. The study is further limi-
ted by the fact that we focused on the necessity and 
possibilities for CRT optimization, and as such did 
not assess clinical or echocardiographic outcome 
in these patients, which was beyond the scope of 
this study. However, evidence is accumulating as 
indicated above that empirical AV delay program-
ming cannot generally be recommended [17]. As 
such, our data do indicate that specialist follow-up 
of CRT recipients is of crucial importance in order 
to provide optimal care for these complex patients, 
which was the primary aim of the current study.
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Conclusions and perspective
In our “real world” cohort, a substantial pro-
portion of patients presented with suboptimal 
device settings. Data from previous studies de-
monstrate that device optimization is associated 
with improved outcome [17, 18]. Yet, our data 
indicate that this opportunity is frequently missed 
in daily clinical practice, underlining the necessity 
for expert follow-up to deliver optimal care to this 
challenging group of heart failure patients in order 
for them to benefit most of their devices.
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